Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of IV Eravacycline in Children
NCT03696550Phase 1Completed
- Sponsor
- Tetraphase Therapeutics
- Start
- Dec 2018
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of eravacycline in bacterial infection (2 cohorts), sponsored by Tetraphase Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration at Day 7, Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration at Day 7 and 5 more. Started Dec 2018; status: completed.
02
Drugs
eravacycline
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03696550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03696550.